

Mononuclear gold(III) complexes with L-histidine-containing dipeptides: tuning the structural and biological properties by variation of the N-terminal amino acid and counter anion

Beata Warżajtis,^a Biljana Đ. Glišić,^b Nada D. Savić,^b Aleksandar Pavić,^c Sandra Vojnović,^c Aleksandar Veselinović,^d Jasmina Nikodinovic-Runic,*^c Urszula Rychlewska*^a and Miloš I. Djuran*^b

^a*Faculty of Chemistry, Adam Mickiewicz University, Umultowska 89B, 61-614 Poznań, Poland*

^b*Department of Chemistry, Faculty of Science, University of Kragujevac, R. Domanovića 12, 34000 Kragujevac, Serbia*

^c*Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11000 Belgrade, Serbia*

^d*Faculty of Medicine, Department of Chemistry, University of Niš, 18000 Niš, Serbia*

*Corresponding authors. Tel.: +381 11 397 6034; fax: +381 11 397 5808 (J. Nikodinovic-Runic); Tel.: +48 61 8291 268; fax: +48 61 829 1555 (U. Rychlewska); Tel.: +381 34 300 251; fax: +381 34 335 040 (M. I. Djuran).

E-mail addresses: jasmina.nikodinovic@gmail.com (J. Nikodinovic-Runic); urszular@amu.edu.pl (U. Rychlewska); djuran@kg.ac.rs (M. I. Djuran).

Abstract

Gold(III) complexes with different L-histidine-containing dipeptides, [Au(Gly-L-His-*N_A,N_P,N₃*)Cl]Cl·3H₂O (**1a**), [Au(Gly-L-His-*N_A,N_P,N₃*)Cl]NO₃·1.25H₂O (**1b**), [Au(L-Ala-L-His-*N_A,N_P,N₃*)Cl][AuCl₄]·H₂O (**2a**), [Au(L-Ala-L-His-*N_A,N_P,N₃*)Cl]NO₃·2.5H₂O (**2b**), [Au(L-Val-L-His-*N_A,N_P,N₃*)Cl]Cl·2H₂O (**3**), [Au(L-Leu-L-His-*N_A,N_P,N₃*)Cl]Cl (**4a**) and [Au(L-Leu-L-His-*N_A,N_P,N₃*)Cl][AuCl₄]·H₂O (**4b**) have been synthesized and structurally characterized by spectroscopic (¹H NMR, IR and UV-vis) and single-crystal X-ray diffraction techniques. The antimicrobial efficiency of these gold(III) complexes, along with K[AuCl₄] and the corresponding dipeptides, was evaluated against the broad panel of Gram-positive and Gram-negative bacteria and fungi, displaying their moderate inhibiting activity. Moreover, cytotoxic properties of the investigated complexes were assessed against the normal human lung fibroblast cell line (MRC5) and two human cancer, cervix (HeLa) and lung (A549) cell lines. None of the complexes exerted significant cytotoxic activity; nevertheless complexes that did show selectivity in terms of cancer vs. normal cell lines (**2a/b** and **4a/b**) have been evaluated using zebrafish (*Danio rerio*) embryos for toxicity and antiangiogenic potential. Although the gold(III) complexes achieved antiangiogenic effect comparable to the known angiogenic inhibitors auranofin and sunitinib malate at 30-fold higher concentrations, they had no cardiovascular side effects, which commonly accompany auranofin and sunitinib malate treatment. Finally, binding of the gold(III) complexes to the active sites of both human and bacterial (*Escherichia coli*) thioredoxin reductases (TrxRs) was demonstrated by molecular docking study, suggesting that the mechanism of biological action of these complexes can be associated with their interaction with the TrxR active site.

Keywords: Gold(III) complexes; L-Histidine-containing dipeptides; Antimicrobial activity; Cytotoxicity; *Danio rerio*; Antiangiogenic activity

TABLE OF CONTENTS

Fig. S1 The dose-dependent inhibition of the subintestinal vessels (SIVs) formation in zebrafish embryos after 48 h of treatments with gold(III)-peptide complexes **2a**, **2b**, **4a** and **4b**. Normally developed SIVs basket with 5 - 9 vessels is denoted in DMSO-treated embryo (dashed circle). Reduction in the size and the number of vessels of SIVs basket upon different treatments are designed with arrowhead. Auranofin (1.25 μ M) and sunitinib malate (1.25 μ M) are used as positive controls, upon which regimes embryos suffered of pericardial edemas (arrow).

Fig. S2 The best docking pose for the corresponding gold(III) complex cation and auranofin inside human thioredoxin reductase active site.

Fig. S3 LigPlot diagrams illustrating interactions between the corresponding gold complexes and human thioredoxin reductase during docking. Hydrogen bonds are illustrated by dashed lines and the donor-acceptor distances are given in Å units. Hydrophobic interactions are represented by red spokes radiating towards the ligand atoms they contact. Amino acids labeled in black form hydrophobic and van der Walls interactions, while those labeled in green form hydrogen bonds with the complex. The interacted atoms are spokes radiating back. C, N, O, S and Au atoms are represented in black, blue, red, yellow and green, respectively.

Fig. S4 The best docking pose for the corresponding gold(III) complex cation and auranofin inside *Escherichia coli* thioredoxin reductase active site.

Fig. S5 LigPlot diagrams illustrating interactions between the corresponding gold complexes and *Escherichia coli* thioredoxin reductase during docking. Hydrogen bonds are illustrated by dashed lines and the donor-acceptor distances are given in Å units. Hydrophobic interactions are represented by red spokes radiating towards

the ligand atoms they contact. Amino acids labeled in black form hydrophobic and van der Walls interactions, while those labeled in green form hydrogen bonds with the complex. The interacted atoms are spokes radiating back. C, N, O, S and Au atoms are represented in black, blue, red, yellow and green, respectively.

Table S1 Selected geometric parameters (Å, °) S22

Table S2 Endocyclic torsion angles (°) for five- and six-membered rings and average endocyclic torsion angle moduli ($|\omega|$) S23

Table S3 Hydrogen bond parameters (Å, °) S25

Table S4 Score values (kcal/mol) for all studied gold complexes for both human and *Escherichia coli* thioredoxin reductases (TrxRs). S29

Table S5 Crystallographic data collection and structure refinement information for gold(III) complexes **2a**, **3**, **4a** and **4b** S30

Table S6 Lethal and teratogenic effects observed in zebrafish (*Danio rerio*) embryos at different hours post fertilization (hpf) S31

References S32

Fig. S1 The dose-dependent inhibition of the subintestinal vessels (SIVs) formation in zebrafish embryos after 48 h of treatments with gold(III)-peptide complexes **2a**, **2b**, **4a** and **4b**. Normally developed SIVs basket with 5 - 9 vessels is denoted in DMSO-treated embryo (dashed circle). Reduction in the size and the number of vessels of SIVs basket upon different treatments are designed with arrowhead. Auranofin (1.25 μ M) and sunitinib malate (1.25 μ M) are used as positive controls, upon which regimes embryos suffered of pericardial edemas (arrow).







Fig. S2 The best docking pose for the corresponding gold(III) complex cation and auranofin inside human thioredoxin reductase active site.




1a/b




2a/b



3




4a/b




Auranofin


Fig. S3 LigPlot diagrams illustrating interactions between the corresponding gold complexes and human thioredoxin reductase during docking. Hydrogen bonds are illustrated by dashed lines and the donor-acceptor distances are given in Å units. Hydrophobic interactions are represented by red spokes radiating towards the ligand atoms they contact. Amino acids labeled in black form hydrophobic and van der Walls interactions, while those labeled in green form hydrogen bonds with the complex. The interacted atoms are spokes radiating back. C, N, O, S and Au atoms are represented in black, blue, red, yellow and green, respectively.




1a/b




2a/b






4a/b




Auranofin


Fig. S4 The best docking pose for the corresponding gold(III) complex cation and auranofin inside *Escherichia coli* thioredoxin reductase active site.




1a/b




2a/b



3




4a/b




Auranofin


Fig. S5 LigPlot diagrams illustrating interactions between the corresponding gold complexes and *Escherichia coli* thioredoxin reductase during docking. Hydrogen bonds are illustrated by dashed lines and the donor-acceptor distances are given in Å units. Hydrophobic interactions are represented by red spokes radiating towards the ligand atoms they contact. Amino acids labeled in black form hydrophobic and van der Walls interactions, while those labeled in green form hydrogen bonds with the complex. The interacted atoms are spokes radiating back. C, N, O, S and Au atoms are represented in black, blue, red, yellow and green, respectively.




1a/b




2a/b



3



4a/b



Auranofin

Table S1 Selected geometric parameters (\AA , $^\circ$)

	[Au(Gly-L-His- <i>N_A,N_P,N₃</i>)Cl]Cl·3H ₂ O (1a) ¹	[Au(Gly-L-His- <i>N_A,N_P,N₃</i>)Cl]NO ₃ ·1.25H ₂ O (1b) ²	[Au(L-Ala-L-His- <i>N_A,N_P,N₃</i>)Cl][AuCl ₄]·H ₂ O (2a)	[Au(L-Ala-L-His- <i>N_A,N_P,N₃</i>)Cl]NO ₃ ·2.5H ₂ O (2b) ²	[Au(L-Val-L-His- <i>N_A,N_P,N₃</i>)Cl]Cl·2H ₂ O (3)	[Au(L-Leu-L-His- <i>N_A,N_P,N₃</i>)Cl]Cl (4a)	[Au(L-Leu-L-His- <i>N_A,N_P,N₃</i>)Cl][AuCl ₄]·H ₂ O (4b)
Au1—N1	2.002(9)	1.987(8) 2.026(10)	2.009(6)	2.018(5)	2.013(8) 2.010(8)	2.004(5)	2.009(5)
Au1—N2	1.94(1)	2.020(10) 2.021(10)	1.987(6)	1.995(5)	1.990(12) 1.991(11)	1.981(5)	1.999(6)
Au1—N3	1.991(8)	1.996(9) 1.913(10)	1.994(7)	2.001(6)	2.012(8) 2.017(9)	2.014(5)	2.002(6)
Au1—Cl1	2.272(3)	2.293(3) 2.297(3)	2.282(3)	2.2868(16)	2.282(2) 2.288(2)	2.2852(17)	2.2788(18)
N1—Au1—N2	84.8	82.8(4) 82.3(4)	83.3(3)	81.7(2)	80.8(4) 81.0(5)	83.2(2)	81.5(2)
N1—Au1—N3	175.6	175.3(4) 175.4(4)	176.3(3)	175.8(2)	176.4(4) 176.4(4)	174.1(2)	174.5(3)
N3—Au1—N2	90.9	92.7(4) 93.2(4)	93.0(3)	94.2(2)	95.7(4) 95.5(5)	94.0(2)	93.6(2)
N1—Au1—C11	88.5	92.5(2) 92.2(3)	90.60(19)	92.93(17)	91.8(3) 92.0(3)	89.15(16)	92.68(18)
N2—Au1—C11	174.3	174.7(3) 174.0(3)	172.7(2)	174.56(17)	172.3(4) 173.0(4)	171.73(17)	173.87(17)
N3—Au1—C11	94.8	92.1(3) 92.4(3)	93.1(2)	91.17(17)	91.7(3) 91.5(3)	93.88(18)	92.31(18)

Table S2 Endocyclic torsion angles ($^{\circ}$) for five- and six-membered rings and average endocyclic torsion angle moduli ($|\omega|$)

	[Au(Gly-L-His- <i>N_A,N_P,N₃</i>)Cl]Cl·3H ₂ O (1a)¹	[Au(Gly-L-His- <i>N_A,N_P,N₃</i>)Cl]NO ₃ ·1.25H ₂ O (1b)²	[Au(L-Ala-L-His- <i>N_A,N_P,N₃</i>)Cl][AuCl ₄]·H ₂ O (2a)	[Au(L-Ala-L-His- <i>N_A,N_P,N₃</i>)Cl]NO ₃ ·2.5H ₂ O (2b)²	[Au(L-Val-L-His- <i>N_A,N_P,N₃</i>)Cl]Cl·2H ₂ O (3)	[Au(L-Leu-L-His- <i>N_A,N_P,N₃</i>)Cl]Cl (4a)	[Au(L-Leu-L-His- <i>N_A,N_P,N₃</i>)Cl][AuCl ₄]- H ₂ O (4b)
five-membered ring							
Au1—N1—C1—C2	0.41	-29.6(15) -18.2(14)	12.1(8)	-28.3(8)	-6.7(11) -12.0(12)	-5.3(7)	-17.6(7)
N1—C1—C2—N2	-2.33	13.1(17) 7.0(19)	-15.8(10)	18.0(10)	-5.1(15) -0.7(16)	5.4(8)	2.6(9)
C1—C2—N2—Au1	3.35	9.6(14) 7.8(17)	12.1(9)	1.4(9)	15.5(15) 13.7(15)	-2.9(7)	14.1(8)
C2—N2—Au1—N1	-2.52	-21.5(10) -14.5(9)	-3.7	-14.3(7)	-15.7 -16.4	-0.2	-19.2
N2—Au1—N1—C1	1.01	27.8(10) 18.1(9)	-5.4	23.3(6)	10.9 14.7	3.2	19.6
$ \omega $	1.9(1.1)	20.3(7.9) 13.1(4.9)	9.8(4.5)	17.1(9.2)	10.8(4.4) 11.5(5.6)	3.4(1.9)	14.6(6.3)
six-membered ring							
Au1—N2—C3—C4	-38.0	-31.9(14) -31.5(18)	-48.2(8)	-34.4(11)	-35.8(13) -39.1(13)	-41.8(8)	-42.0(8)
N2—C3—C4—C5	71.1	67.7(14) 63.4(18)	65.4(9)	66.8(9)	69.4(12) 68.9(13)	59.5(8)	67.0(8)
C3—C4—C5—N3	-54.1	-65(2) -49.7(19)	-41.0(11)	-54.6(10)	-54.1(13) -52.3(14)	-43.6(10)	-43.0(10)
C4—C5—N3—Au1	2.2	20(3) 0.9(19)	-1.1(11)	8.9(10)	4.5(12) 5.4(13)	7.3(9)	-4.9(9)

C5—N3—Au1—N2	23.8	11.9(19)	14.8	17.5(6)	21.0	8.2	22.9
N3—Au1—N2—C3	-3.8	22.3(13)			18.5		
ω	32(25)	-5.1(11)	10.6	-3.6(8)	-4.7	10.5	1.9
		-6.3(12)			-0.4		
		34(24)	30(23)	31(23)	32(24)	28(21)	30(23)
		29(22)			31(25)		

Table S3 Hydrogen bond parameters (\AA , $^\circ$)

$D-\text{H}\cdots A$	$D-\text{H} (\text{\AA})$	$\text{H}\cdots A (\text{\AA})$	$D\cdots A (\text{\AA})$	$D-\text{H}\cdots A (^\circ)$	Symmetry operations on A
[Au(Gly-L-His- $N_A,N_P,N3$)Cl] \cdot 3H ₂ O (1a)¹					
O3—H11 \cdots O5	0.97	1.66	2.618	174	
N1—H1 \cdots Cl2	0.95	2.21	3.150	170	
N1—H2 \cdots O6	0.94	1.84	2.776	171	
N4—H9 \cdots O4	0.95	1.84	2.758	161	
C7—H10 \cdots O2	0.96	2.44	3.173	133	$-x+1,+y+1/2,-z$
[Au(Gly-L-His- $N_A,N_P,N3$)Cl] \cdot NO ₃ \cdot 1.25H ₂ O (1b)²					
O3—H3O \cdots O1N	0.82	2.03	2.680(15)	135	
N1—H1N \cdots O2W	0.90	2.07	2.961(14)	171	$x-1/2,+y+1/2,+z$
N1—H2N \cdots O1	0.90	2.16	2.876(18)	136	$-x+1/2+1,+y-1/2,-z+2$
N1—H2N \cdots Cl1'	0.90	2.82	3.491(18)	133	$x,+y-1,+z$
N4—H4N \cdots O4N	0.86	2.52	3.231(19)	141	
N4—H4N \cdots O6N	0.86	2.08	2.901(21)	159	
C6—H6 \cdots O3	0.93	2.65	3.397(18)	138	$-x+2,+y,-z+2$
C7—H7 \cdots O2'	0.93	2.40	3.317(19)	168	
O3' \cdots H3O' \cdots O1W	0.82	1.92	2.709(18)	162	
N1' \cdots H1N' \cdots O2W	0.90	2.05	2.932(15)	166	$x-1/2,+y+1/2,+z$
N1' \cdots H2N' \cdots O5N	0.90	2.11	2.971(16)	161	$x-1/2,+y+1/2,+z$
N1' \cdots H2N' \cdots O1'	0.90	2.68	3.202(15)	118	$-x+1/2+1,+y+1/2,-z+1$
N4' \cdots H4N' \cdots O1N	0.86	2.00	2.849(16)	170	$-x+2,+y,-z+2$

N4'—H4N'…O2N	0.86	2.56	3.062(17)	118	-x+2,+y,-z+2
C6'—H6'…O2N	0.93	2.61	3.098(22)	113	-x+2,+y,-z+2
C7'—H7'…O2	0.93	2.33	3.108(17)	141	
[Au(L-Ala-L-His- <i>N_A,N_P,N₃</i>)Cl][AuCl ₄]·H ₂ O (2a)					
O3—H3O…O1W	0.82	1.81	2.620(7)	170	
N1—H1A…O1	0.89	1.98	2.824(8)	159	-x+1/2+1,+y-1/2,-z+1
N1—H1B…Cl5	0.89	2.48	3.364(6)	173	
N4—H4…Cl2	0.86	2.61	3.358(10)	146	x,+y,+z+1
N4—H4…Cl2	0.86	2.72	3.279(10)	124	-x+1,+y,-z+1
C7—H7…Cl5	0.93	2.97	3.562(10)	123	x,+y,+z+1
O1W—H1W…O1	0.82	2.00	2.823(9)	179	x,+y,+z+1
O1W—H2W…O2	0.82	2.05	2.868(11)	180	-x+1/2+1,+y+1/2,-z+2
[Au(L-Ala-L-His- <i>N_A,N_P,N₃</i>)Cl]NO ₃ ·2.5H ₂ O (2b) ²					
O3—H3O…O1W	0.82	1.85	2.653(14)	168	
N1—H1N…O2W	0.90	2.00	2.887(9)	170	
N1—H2N…O3W	0.90	2.26	3.142(14)	165	
N4—H4N…O1N	0.86	2.52	3.189(21)	135	
N4—H4N…O2N	0.86	1.96	2.808(19)	170	
N4—H4N…O1N'	0.86	2.08	2.890(29)	157	
N4—H4N…O3N'	0.86	2.33	3.069(38)	144	
C6—H6…O1W	0.93	2.83	3.489(11)	128	-x+1/2+1,+y-1/2,-z+1
C7—H7…O2	0.93	2.22	3.112(9)	160	-x+2,-y+1,+z
[Au(L-Val-L-His- <i>N_A,N_P,N₃</i>)Cl]Cl·2H ₂ O					

(3)					
O3—H3A…O4W	0.82	1.80	2.534(16)	148	x,+y,+z-1
N1—H1A…O2W	0.89	1.94	2.810(13)	167	
N1—H1B…O1W	0.89	2.16	2.922(15)	143	
N4—H4…Cl4	0.86	2.20	3.040(9)	167	
C7—H7…O22	0.93	2.27	3.170(12)	162	
O23—H23A…O3W	0.82	1.80	2.611(13)	171	
N21—H21A…O2W	0.89	1.94	2.808(10)	166	
N21—H21B…O1W	0.89	2.30	3.010(11)	137	x-1,+y,+z
N24—H24…Cl3	0.86	2.24	3.072(15)	162	
O1W—H11W…Cl3	0.82	2.38	3.202(8)	180	x+1,+y+1,+z
O1W—H12W…Cl4	0.82	2.36	3.166(9)	169	x,+y+1,+z
O2W—H21W…Cl3	0.82	2.24	3.054(8)	170	x,+y+1,+z
O2W—H22W…Cl4	0.82	2.28	3.062(11)	158	x,+y+1,+z
O3W—H31W…Cl4	0.82	2.37	3.177(11)	167	
O3W—H32W…O1	0.82	1.93	2.749(11)	180	x,+y-1,+z+1
O3W—H42W…O21	0.82	1.91	2.730(14)	180	
O4W—H41W…Cl3	0.82	2.43	3.197(9)	157	x,+y,+z+1
[Au(L-Leu-L-His- <i>N_A,N_P,N₃</i>)Cl]Cl (4a)					
O3—H3O…Cl2	0.82	2.26	3.079(5)	176	
N1—H1A…O2	0.89	2.19	2.879(9)	134	-x+1,+y-1/2,-z+1/2
N1—H1A…Cl2	0.89	2.68	3.365(6)	134	-x+1,+y-1/2,-z+1/2
N1—H1B…Cl2	0.89	2.51	3.356(6)	160	x,+y-1,+z
N4—H4…Cl2	0.86	2.39	3.167(6)	151	-x+2,+y-1/2,-z+1/2

C3—H3…O1	0.98	2.32	2.728(9)	104	
C6—H6…Cl1	0.93	2.68	3.549(8)	156	-x+2,+y+1/2,-z+1/2
C7—H7…O1	0.93	2.59	3.441(9)	152	-x+1/2+1,-y+1,+z-1/2
[Au(L-Leu-L-His- <i>N_A,N_P,N₃</i>)Cl][AuCl ₄]·H ₂ O (4b)					
O3—H3A…O1	0.82	1.91	2.718(9)	167	-x+2,+y+1/2,-z+1/2+1
N1—H1A…O1W	0.89	1.82	2.701(8)	174	
N1—H1B…Cl5	0.89	2.44	3.323(6)	171	
N4—H4…Cl4	0.86	2.88	3.563(7)	138	x,+y+1,+z
N4—H4…Cl5	0.86	2.65	3.372(7)	142	x,+y+1,+z
C7—H7…Cl1	0.93	2.73	3.169(9)	110	
C7—H7…Cl2	0.9	2.87	2.484(9)	125	x-1/2,-y+1/2+1,-z+1
O1W—H1W…Cl4	0.82	2.56	3.375(7)	180	x-1/2,-y+1/2,-z+1
O1W—H2W…O2	0.82	2.03	2.787(9)	153	-x+1,+y-1/2,-z+1/2+1

Table S4 Score values (kcal/mol) for all studied gold complexes for both human and *Escherichia coli* thioredoxin reductases (TrxRs)

Complex	HBond	NoHBond	Steric	VdW	Energy	MolDock score	Rerank score	LE1	LE3
Human TrxR									
1a/b	-10.3001	-15.7147	-97.6026	-28.3324	-107.792	-117.767	-93.4174	-6.34069	-5.49514
2a/b	-8.28748	-12.987	-100.515	8.58733	-100.891	-113.659	-67.7239	-5.60504	-3.76244
3	-8.83728	-20.0669	-102.647	-10.8993	-110.66	-128.054	-83.9307	-5.53298	-4.19654
4a/b	-8.24472	-19.3412	-112.94	-20.772	-114.527	-131.499	-90.69	-5.45368	-4.31857
auranofin	-15.0274	-26.5616	-146.155	21.3618	-153.482	-143.236	-82.942	-4.95102	-2.67555
<i>E. coli</i> TrxR									
1a/b	-10.518	-19.1302	-95.1559	-13.3679	-101.493	-117.791	-76.8644	-5.97016	-4.52143
2a/b	-9.44207	-13.5791	-98.9944	34.371	-100.694	-112.804	-52.7091	-5.5941	-2.92828
3	-3.58192	-16.8204	-106.373	5.59057	-111.03	-133.064	-77.7934	-5.55152	-3.88967
4a/b	-4.85869	-15.3973	-116.986	-25.9755	-112.269	-132.434	-90.7863	-5.34613	-4.32316
auranofin	-4.83363	-12.0032	-175.936	-44.9353	-167.046	-172.59	-129.802	-5.38859	-4.18717

Table S5 Crystallographic data collection and structure refinement information for gold(III) complexes **2a**, **3**, **4a** and **4b**

	2a	3	4a	4b
Crystal data				
Chemical formula	C ₉ H ₁₅ Au ₂ Cl ₅ N ₄ O ₄	C ₁₁ H ₂₁ AuCl ₂ N ₄ O ₅	C ₁₂ H ₁₉ AuCl ₂ N ₄ O ₃	C ₁₂ H ₂₁ Au ₂ Cl ₅ N ₄ O ₄
M _r	814.43	557.18	535.18	856.51
Crystal system, space group	Monoclinic, <i>C</i> 2	Triclinic, <i>P</i> 1	Orthorhombic, <i>P</i> 2 ₁ 2 ₁ 2 ₁	Orthorhombic, <i>P</i> 2 ₁ 2 ₁ 2 ₁
<i>a</i> , <i>b</i> , <i>c</i> (Å)	27.3091(7), 8.6678(2), 8.6743(2)	6.9310(4), 11.7421(7), 12.5963(8)	9.8509(2), 10.7911(2), 15.3736(3)	8.3519(1), 11.1268(1), 24.3707(2)
α, β, γ (°)	90, 108.081(2), 90	68.927(6), 79.453(5), 88.221(5)	90, 90, 90	90, 90, 90
<i>V</i> (Å ³)	1951.90(8)	939.75(11)	1634.25(6)	2264.77(4)
<i>Z</i>	4	2	4	4
μ (mm ⁻¹)	15.72	8.14	9.35	13.56
Crystal size (mm)	0.45 × 0.35 × 0.35	0.45 × 0.20 × 0.13	0.20 × 0.15 × 0.15	0.25 × 0.10 × 0.07
Data collection				
<i>T</i> _{min} , <i>T</i> _{max}	0.019, 0.070	0.105, 0.532	0.300, 0.505	0.113, 0.528
No. of measured, independent and observed [<i>I</i> >2σ(<i>I</i>)] reflections	18553, 3462, 3403	21633, 6620, 6230	18637, 2895, 2795	40694, 3993, 3835
<i>R</i> _{int}	0.038	0.028	0.040	0.038
(sin θ/λ) _{max} (Å ⁻¹)	0.595	0.595	0.595	0.595
Refinement				
<i>R</i> [<i>F</i> ² >2σ(<i>F</i> ²)], <i>wR</i> (<i>F</i> ²), <i>S</i>	0.017, 0.042, 1.09	0.023, 0.055, 1.06	0.019, 0.039, 1.03	0.018, 0.041, 1.05
No. of reflections	3462	6620	2895	3993
No. of parameters	220	421	203	245
No. of restraints	1	3	0	0
Δρ _{max} , Δρ _{min} (e Å ⁻³)	0.70, -0.61	0.90, -0.48	0.62, -0.39	0.66, -0.76
Absolute structure parameter	-0.025(4)	-0.012(4)	-0.016(5)	-0.015(3)

Table S6 Lethal and teratogenic effects observed in zebrafish (*Danio rerio*) embryos at different hours post fertilization (hpf)

Category	Developmental endpoints	Exposure time (hpf)			
		24	48	72	96/114
Lethal effect	Egg coagulation ^a	●	●	●	●
	No somite formation	●	●	●	●
	Tail not detached	●	●	●	●
	No heartbeat		●	●	●
Teratogenic effect	Malformation of head	●	●	●	●
	Malformation of eyes ^b	●	●	●	●
	Malformation of sacculi/otoliths ^c	●	●	●	●
	Malformation of chorda	●	●	●	●
	Malformation of tail ^d	●	●	●	●
	Scoliosis	●	●	●	●
	Heartbeat frequency		●	●	●
	Blood circulation		●	●	●
	Pericardial edema	●	●	●	●
	Yolk edema	●	●	●	●
	Yolk deformation	●	●	●	●
	Growth retardation ^e	●	●	●	●

^aNo clear organs structure is recognized.^bMalformation of eyes was recorded for the retardation in eye development and abnormality in shape and size.^cPresence of no, one or more than two otoliths per sacculus, as well as reduction and enlargement of otoliths and/or sacculi (otic vesicles).^dTail malformation was recorded when the tail was bent, twisted or shorter than to control embryos as assessed by optical comparation.^eGrowth retardation was recorded by comparing with the control embryos in development or size (before hatching, at 24 hpf and 48 hpf) or in a body length (after hatching, at and onwards 72 hpf) using by optical comparation using a inverted microscope (CKX41; Olympus, Tokyo, Japan).

References

- 1 M. Wienken, B. Lippert, E. Zangrando and L. Randaccio, *Inorg. Chem.*, 1992, **31**, 1983-1985.
- 2 U. Rychlewska, B. Waržajtis, B. Đ. Glišić, M. D. Živković, S. Rajković and M. I. Djuran, *Dalton Trans.*, 2010, **39**, 8906-8913.